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Abstract 
Background: The World Health Organization (WHO) recommends consideration of mass drug administration (MDA) 
for malaria control in low‑endemic settings approaching elimination. However, MDA remains a controversial strategy, 
as multiple individual, social, and operational factors have shown to affect its acceptability at local levels. This is further 
complicated by inconsistent definitions of key indicators derived from individual and community involvement—cov‑
erage, adherence, and compliance—that cast doubts about the actual and potential epidemiological impact of MDA 
on disease control and elimination. This study aimed to identify limitations and enabling factors impacting involve‑
ment at different stages of a large cluster‑randomized trial assessing the effect of combining dihydroartemisinin‑pipe‑
raquine (DP) and ivermectin (IVM) in malaria transmission in The Gambia.
Methods: This social science study used a mixed‑methods approach. Qualitative data were collected in intervention 
and control villages through ethnographic methods, including in‑depth interviews (IDIs), focus group discussions 
(FGDs), and participant observation conducted with trial participants and decliners, community leaders, and field staff. 
A cross‑sectional survey was conducted in the intervention villages after the first year of MDA. Both strands of the 
study explored malaria knowledge and opinions, social dynamics influencing decision‑making, as well as perceived 
risks, burdens, and benefits associated with this MDA.
Results: 157 IDIs and 11 FGDs were conducted, and 864 respondents were included in the survey. Barriers and 
enabling factors to involvement were differentially influential at the various stages of the MDA. Issues of social influ‑
ence, concerns regarding secondary effects of the medication, costs associated with malaria, and acceptability of the 
implementing organization, among other factors, differently affected the decision‑making processes throughout the 
trial. Rather than a linear trajectory, involvement in this MDA trial was subjected to multiple revaluations from enrol‑
ment and consent to medicine intake and adherence to treatment.
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Background
Mass drug administration (MDA) is an intervention 
that aims at reducing the human reservoir of malaria 
infection by administering a full antimalarial treatment 
to the whole population, regardless of the individual’s 
infection status. This approach has been successfully 
implemented to control several neglected tropical dis-
eases [1]. The World Health Organization (WHO) 
recommends the consideration of MDA for malaria 
control in endemic island communities and in low-
endemic non-island settings approaching elimination, 
such as The Gambia, where there is minimal risk of 
re-introduction of infection, good access to treatment, 
and implementation of vector control and surveillance 
[2]. However, MDA remains controversial. A Cochrane 
systematic review concluded that MDA substantially 
reduces the risk of malaria infection, but few studies 
have shown a sustained impact beyond 6 months post-
MDA [3]; further, MDA may increase the risk of select-
ing drug resisistance parasites [4]. Studies have also 
shown that achieving and sustaining high coverage is 
likely more important than the treatment used [5]. This 
requires the involvement of the target populations for 
as long as necessary in order to achieve the expected 
epidemiological outcomes, especially as a consistent 
trend of reduced MDA uptake over time, particularly in 
multidose regimens, has been observed [6].
Multiple individual, social, and operational factors 
have shown to influence acceptability and adherence 
to MDA. These include scepticism towards allopathic 
medicine [7], reluctance to undergo screening proce-
dures like blood sampling [8] and pregnancy tests [9], 
concerns on drug adverse reactions [10], and reluc-
tance of taking treatment without any symptoms [11]. 
Lack of clarity regarding the specific drug regimens 
administered [12], mobility [9], and mistrust between 
those who distribute the medications and local popula-
tions [13] have also been identified as factors decreas-
ing treatment coverage and compliance. Implementing 
organizations also play a significant role in facilitating 
or limiting local involvement in MDA. Operational 
and implementation issues, such as providing ade-
quate information, designing field staff supervision 
responsibilities, and preparing health systems for the 
intervention, heavily rely on management decisions and 
existing health policies at the national and local levels 
[14].
Lack of clarity regarding key MDA performance indi-
cators such as coverage, compliance, and adherence 
contributes to the scepticism on MDA effectiveness. A 
systematic review on MDA strategies observed meth-
ods to estimate coverage and compliance are often not 
reported [7] or, when reported, definitions vary. Cover-
age may be estimated by taking the whole population 
[15], residents in smaller units of analysis (household or 
compounds) [16], or only those eligible for treatment 
[17]. Trials also differ on the amount of doses neces-
sary to determine adherence to treatment. This can 
be as little as receiving treatment at any point in the 
intervention [17], completing a component of the treat-
ment [18], or taking the full medication regimen [19]. 
The inconsistencies in the definitions and use of these 
indicators have a direct impact on the quality of the 
data collected, and, ultimately, on the arguments used 
to justify MDA implementation in already constrained 
health systems [20–22].
It has been recently suggested that ivermectin (IVM), 
commonly used for the control of onchocerciasis and 
lymphatic filariasis, may also play a role in malaria con-
trol and elimination. Indeed, IVM is toxic to Anopheles 
mosquitoes when they take a blood meal from a host 
that has recently received the drug. This provides the 
opportunity of killing mosquitoes that have escaped 
conventional vector control interventions [23], e.g. 
those that bite outdoors [24, 25]. Combining an effica-
cious anti-malarial with IVM may have a synergistic 
effect as the former would reduce the population para-
site biomass and provide post-treatment prophylaxis 
while the latter would reduce vector densities [26, 27]. 
Eventually, IVM would reduce the minimal coverage 
required by MDA as mosquitoes, by feeding on several 
individuals over a short period, may also take a toxic 
dose of IVM from one of them. Transmission models 
suggest that adding IVM to a MDA intervention may 
interrupt transmission where standard MDA would be 
insufficient [28].
Factors influencing the decision-making process 
at different stages of an MDA implementation pro-
cess, from enrolment to adherence, were investigated 
Conclusions: This study went beyond the individual factors often associated with coverage and adherence, and 
found that nuanced social dynamics greatly influence the decision‑making process at all phases of the trial. These 
issues need to be consider for MDA implementation strategies and inform discussions about more accurate ways of 
reporting on critical effectiveness indicators.
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in the framework of a large cluster randomized trial 
(the MASSIV trial) assessing the effect of MDA with 




The trial was implemented in the Upper River Region 
(URR) in eastern Gambia, where the incidence of 
malaria is 1.7/PYAT [29]. This is an area of marked 
seasonal malaria transmission, with low vector density 
and high vector survival (parous rate 81–91% in URR 
as compared to 27–71% in other regions)[29]. Despite 
high coverage of standard control interventions—
namely long-lasting insecticidal nets (LLINs), indoor 
residual spraying (IRS), Seasonal Malaria Chemopre-
vention (SMC), and artemisinin-based combination 
therapy (ACT)—URR is the Gambian region with the 
highest burden of malaria [30].
Thirty two study villages with a population between 
140 and 700 each were identified in the south bank of 
the URR and randomly assigned to either the interven-
tion or the control arm. Most villages were inhabited 
by a single ethnic group, the most common of which 
was Fula followed by Mandinka. Villages are led by 
an Alkalo, or village chief, and are made up of com-
pounds, an enclosed space containing one or several 
households belonging to the same extended patrilin-
eal family. The main economic activity is subsistence 
farming with a heavily reliance on remittances [31].
Prior to the MASSIV trial’s enrolment process, com-
munity sensitization meetings took place in all trial 
villages. Sensitization meetings were events where the 
trial and its details were introduced to the community 
by MRC field staff after receiving permission from the 
village Alkalo. The intervention was implemented with 
3 MDA rounds per year, for 2  years, just before and 
at the beginning of the malaria transmission season. 
During each round, DP and IVM were administered 
as pills at the recommended dosage according to body 
weight over the course of 3  days. The primary end-
point was malaria prevalence determined by molecular 
methods at the peak of the second transmission season 
(November 2019) [32]. Data reported in this manu-
script correspond to the first year of intervention.
Study design
This social sciences study used a sequential explora-
tory mixed-methods design (QUAL ≥ quan) [33]. Ini-
tial qualitative research was implemented between July 
and November 2018, starting before the community 
sensitization meetings and lasting through the third 
MDA round. Data were collected in all villages, inter-
vention and control alike, and informed the design of 




This strand focused on understanding the decision-
making process for both those who accepted and 
declined being part of the trial, the trial effects on the 
residents’ daily activities, and the barriers and enabling 
factors facilitating uptake of the intervention at individ-
ual, family and community level.
Data collection
Initial qualitative research was conducted through 
ethnographic observations of all trial components, 
including sensitization meetings, the consent and trial 
enrolment processes, as well as treatment administra-
tion in all intervention villages. In-depth interviews 
(IDIs) and focus group discussions (FGDs) were con-
ducted with the aid of trained field workers fluent in 
local languages.
Sampling strategy
Selection was purposive to allow for maximum varia-
tion and to further explore emergent themes. Commu-
nity leaders, individuals who accepted or declined to 
take part in the trial, research team, and relevant stake-
holders identified by the study team were included in 
this study.
Data analysis
Qualitative analysis was a continuous, flexible, and iter-
ative process, where data were analysed in the field and 
further research was conducted to confirm or refute 
preliminary findings until saturation was reached. All 
discussions were recorded and transcribed verbatim 
by the research team. Raw data were processed in their 
textual form and coded to generate analytical themes 
for further analysis using NVivo Qualitative Data Anal-
ysis software (CITE software).
Quantitative strand
Rationale
The survey focused on knowledge of the trial, decision-
making processes around involvement, spread of trial-
related information, and social influences, as well as 
perceived risks, burdens, and benefits. In addition, data 
were collected on the details and costs associated with the 
last time the respondents sought treatment for malaria. 
The questions and potential responses were framed upon 
the initial findings of the qualitative research strand.
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Data collection
A cross-sectional survey was carried out in all 16 
intervention villages and targeted individuals aged 
at least 12  years, regardless of level of involvement in 
the trial. Surveys were administered using Epi Info v. 
7 by trained field workers using Android tablets. Data 
were synchronized with each tablet daily and regularly 
checked for quality. Once all surveys were conducted, 
data were exported into Excel to be analysed in STATA 
version 13.
Sampling
A sample size of 850 (rounded up to 900) was calcu-
lated  in order to estimate an odds ratio of at least 1.5 
as part of a multinomial logit regression for an outcome 
variable  with  3 levels (no adherence, low adherence, 
and high adherence).  However,  during the analysis 
stage, the decision was made to combine no and low 
adherence into one category,  resulting in binary logis-
tic regression (no/low adherence and high adherence), 
which, incidentally, has lower sample size require-
ments. Per-village sample size targets were based on 
the proportion of the village’s population size to the 
total population of all intervention villages. Respond-
ents were randomly selected from census data collected 
by the research team in November 2018. If a selected 
individual was unavailable or declined to be surveyed, 
another individuals of the same gender and age bracket 
was recruited from the census data.
Data analysis
Statistical analysis included frequencies of relevant varia-
bles based on survey responses and bi- and multi-variate 
analysis of selected variables to test for associations and 
predictors of the main outcome variables. To mirror the 
general criteria used by the trial, the analysis considered 
four endpoints:
1. Consent and enrolment: the proportion of surveyed 
individuals who self-reported providing written 
informed consent to participate in the trial (some of 
whom signed with their thumbprint);
2. Coverage: the proportion of surveyd individuals 
included in this study who stated having taken the 
trial medication at least once at any point during the 
MDA;
3. Self-reported adherence: the proportion of individu-
als self-reporting the number of days having taken 
the medication, classified as: (a) no/low adherence 
(0–6 times) and (b) high adherence (7–9 times);
4. Clinical card adherence: the proportion of surveyed 
individuals with (a) no/low adherence (0–6 times) or 
(b) high adherence (7–9 times) according to the clini-
cal cards provided by the trial.
Ethics
All respondents and their guardians (when under 
18  years old) were explained the purpose of the study 
by field staff and gave informed consent or assent before 
being included in the qualitative or quantitative strands. 
Considering that the act of signing documents is not 
common practice for local populations and that it could 
produce mistrust towards the study team, we favored oral 
over written consent. Both studies were approved by the 
Institutional Review Board of the Institute of Tropical 
Medicine, Antwerp, Belgium, by the Scientific Coordi-
nating Committee and the Gambian Government/MRC 




There were 157 in-depth and key informant interviews 
and 11 Focus Group Discussions (FGDs) conducted 
across the 32 villages. Respondents included village 
inhabitants, many of them holding community posi-
tions such as Alkalos, Chair of the Village Development 
Committees (VDC), traditional birth attendants (TBAs), 
village health workers (VHWs), and youth leaders. In 
addition, village residents, regardless of whether or not 
they took part in the trial, and MRC field staff were inter-
viewed. Most respondents were women, belonging to the 
Fula ethnic group, and engaged in farming as their pri-
mary activity.
Quantitative strand
The survey included 864 respondents across the 16 inter-
vention villages. There were no refusals. The majority 
of respondents were female (66%), belonged to the Fula 
ethnic group (73%), and listed farming as their primary 
activity (80%). The median age was 29 (IQR: 19–41); 34% 
(294/864) reported previous participation in MRCG-affil-
iated research or programmes (Table 1).
Involvement in the MDA trial
Consent and enrolment, coverage, and adherence
Overall, 722 (84%) survey respondents self-reported 
to have provided written informed consent/assent 
and enrolled in the clinical trial; 70% (606) had taken 
the treatment at least once. Almost two third (62%, 
534/864) of respondents self-reported no/low adher-
ence and the rest (38%) high adherence. The trial 
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clinical card was available at the time of the survey 
for 295 (34%) individuals; about half 45% (134/295) 
had evidence of low adherence (Table 2). It was possi-
ble, with the trial clinical card, to estimate adherence 
by round. The highest uptake was achieved by the first 
MDA round, followed by the third round. In addition, 
during each round, uptake decreased fron dose 1 to 
dose 3 (Fig. 1). Self-report of treatment (mean 6.9; SD 
2.7) was very similar yet significantly higher than the 
information on the trial card (mean 6.5; SD 2.7) (paired 
ttest p-value = 0.001), though the values were highly 
correlated (0.7).
Barriers to individual involvement in the MDA
Multiple factors affected respondents’ abilities or desires 
to take the trial medication. Some factors were more 
relevant at particular phases of the trial; others, such as 
farming responsibilities, were reported as relevant in all 
phases, from enrollment to adherence. Interestingly, of 
those who had enrolled in the trial, 16% (n = 142) did not 
take the medication. Some of them, though enthusiastic 
to enrol and promote uptake of the intervention among 
their communities, never intended to be treated:
“R: We went from one compound to another to 
inform them to come out [because] the MRC staffs 
have come.
I: Did you take the medication?
R: I did not take the medicine because of the reason 
I told you that after I take medicine it makes me sick 
and makes me vomit.” (Village TBA).
“R: Since they [MRC] start to give medication in the 
village I was the one working with them. I have not 
had anyone complain that he or she will not drink 
the medication anymore when the MRC people 
bring the medication.
I: Do you drink the medication?
R: No, I have not drunk the medication.
I: Why is it that?
R: You know since the MRC people came here, I 
am the one attached working with them. I had an 
emergency: one of my sisters was sick in [another vil-
lage], her husband was not there, and I was the one 
responsible to take her to the health facility. Before 
I came back, I found that time has delayed, so that 
was the reason why I could not drink the medica-
tion.” (Male adult).
Travel/mobility
Having travelled or temporarily being away from the vil-
lage was the primary reason for not enrolling in the trial 
(47% of those who did not enroll) or not taking all nine 
doses of the study medication (41% of those who took < 9 
doses) (Table  3). Those in the age category 18–25  years 
were significantly less likely to take the medicine at all or 
have high adherence (Additional file 1: Table S1). When 
asked to elaborate on this finding, respondents explained 
that this age group was the least likely to take part on 
Table 1 Demographic information of surveyed respondents
N = 864 n (%)
Age
 Median (IQR) 29 (19–41)
 Mean (SD) 32.5 (16.1)
Gender
 Male 295 (34)
 Female 566 (66)
Ethnic group
 Fula 626 (73)
 Mandinka 172 (20)
 Serahule 56 (5)
 Other 9 (1)
Marital status
 Never married 240 (28)
 Married 580 (67)
 Separated/divorced 9 (1)
 Widowed 31 (4)
Primary activity
 None 65 (8)
 Farming 694 (80)
 Herding 65 (8)
 Business/trade 131 (15)
 Domestic work 263 (30)
 Other 56 (6)
Education
 None 357 (41)
 Standard 243 (28)
 Quranic 261 (30)
Household status
 Compound head 69 (8)
 Household head 24 (3)
 Compound member 226 (26)
 Wife 360 (42)
 Child 182 (21)
 Other 2 (0)
Previous MRC experience
 Yes 294 (34)
 None 547 (64)
 Does not know 10 (1)
 Does not remember 3 (0)
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the trial because they travel for employment opportuni-
ties. Though some may return to assist in farming, young 
menwere the most likely to travel to the coast or abroad 
during the time of the MDA:
“No, I didn’t drink the medication. By then I was at 
the North Bank doing some electrical work. It seems 
like I am the guardian, but I don’t drink the medica-
tion because that very day didn’t find me here. But 
my wife and my children have all taken the medica-
tion.” (Village mobilizer).
Being away from the village at the the time of the 
MDA round and time constraints related to economic 
activities—particularly farming—were also important 
reasons for not enrolling in the trial or not fully adhering 
to medication: 18% of those who did not enroll and 17% 
of those who did not complete it stated it was because 
they were too busy at that time (Table  3). This can be 
explained by the fact that the timing of the MDA and 
malaria season overlaps heavily with the rainy season, 
the most intense period of agricultural production in this 
region:
“Some people are working on their groundnuts and 
coos farms, this is what we depend on for survival. 
We have only two months remaining for the farming 
period to be completed so we need to work harder.” 
(VDC Chairman).
















Based on self report
 Consent and enrolment 722 (84) – – –
 Coverage (1 or more doses) 606 (70) 606 (84) – –
 No/low adherence (0–6 doses) 534 (62) 392 (54) 276 (46) 115 (40)
  High adherence (7–9 doses) 330 (38) 330 (46) 330 (55) 173 (60)
Based on clinical card
 No/low adherence (0–6 doses) 134 (16) 133 (18) 130 (21) 134 (45)
 High adherence (7–9 doses) 161 (19) 160 (22) 158 (26) 161 (55)
Fig. 1 Percent of surveyed respondents with clinical cards who took trial medication by dose and round
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Implementation issues
Implementation issues impacting medicine uptake 
included misinterpreting or disagreeing with the condi-
tions or logistics of the MDA, such as distribution times 
and locations, enrolment opportunities, and eligibility 
criteria. The requirement to fast for 3 h before and after 
medicine intake (for DP) was said to be an obstacle for 
their regular activities (such as farming) and, for some, 
was sufficient to refuse taking the medication.
Lack of privacy
As part of the eligibility requirements, women of repro-
ductive age (15–49 years old) were required to undergo 
a pregnancy test. The implementation of the pregnancy 
tests varied by village, but it was often a source of con-
cern due to privacy and other issues. In several villages, 
the location of the MDA lacked a private toilet facility 
and the results were often read at the same table where 
people registered. In some cases, women went home to 
collect their sample, but this required carrying an urine 
sample across the village. For many, particularly younger 
women and adolescents, this was a sufficient reason not 
to enrol or return for additional doses of the medication:
“We all [the entire compound] went to take the med-
icine, but I was asked to give my urine sample. I told 
them I am not married, and if it is about pregnancy, 
I know nothing has happened to me but they insisted 
that I must give my urine sample before they give me 
the medicine (…) Because the entire compound was 
there, and they asked me to give my urine sample, 
I refused because I am NOT having any relation-
ship with any man, so I would not do it.” (Adolescent 
female).
“R: It [the pregnancy test] was done in the open 
[space], so people were sitting there. When you come 
and give them the urine sample, they will place it 
there and people will be sitting there looking at it 
(…) It should not happen like that.
I: And when did you decide to stop taking the medi-
cine?
R: I stopped taking the medicine last month.
I: Can you tell us why? Anything that made you to 
stop taking the medicine?
R: Nothing happened, just on menstruation those 
days. That is why I did not go there.” (Adult female).
Knowledge of medicine and perceived side effects
Respondents’ personal beliefs also played a role in deter-
mining whether to enrol in the trial or continue taking 
the medicine. Some stated that they were too old for the 
treatment and others did not consider allopathic medi-
cine as the most effective course of action for treating 
malaria:
“Well, it is a long time I don’t drink medication; I 
mostly depend on herbs.” (Village TBA).
Among those surveyed, 13% said they did not enrol 
and 10% said they did not fully adhere due to what they 
considered side effects of the medication (Table 3). Side 
Table 3 Reasons for not enroling in trial or completing full regimen based on surveyed respondents. Respondents could choose more 
than one reason
Pleae see “Additional File 1: Table S1”
Reasons for not enrolling in trial n = 140
n (%)
Reasons for not taking full regimen n = 566
n (%)
Did not know reason for medicines 5 (4) Did not know more than 1 dose/round 4 (1)
Pregnant 14 (10) Did not know MRC was coming 10 (2)
Sick at time 6 (4) Told to come later 4 (1)
Away from village 66 (47) Ate before 1 (0)
Would not be here for MDA 1 (1) Away from village 234 (41)
Busy at time 25 (18) Too busy 96 (17)
Afraid of side effects 18 (13) Side effects of medication 59 (10)
Healthy; does not need meds 2 (1) Meds made others sick 12 (2)
Too much medicine 1 (1) Too much medicine 11 (2)
Did not attend sensitization 2 (1) Did not like taste 17 (3)
Does not like medicine 10 (7) Got malaria 2 (0)
Medicines do not work 0 (0) Took too much time 0 (0)
Did not want to fast 1 (1) Other 34 (6)
Does not know 6 (4) Does not know 7 (1)
No answer 1 (1) No answer 5 (1)
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effects reported by respondents during IDIs included 
excessive sweating, diarrhoea, vomiting, rash, dizziness, 
stomach pain, and burning chest or heart. Respondents 
reported having stopped the medicine intake as a result 
of personally experiencing or hearing of other commu-
nity members with such symptoms:
“I have drunk the medication once, but I don’t con-
tinue drinking it anymore because since I drink the 
medication day before yesterday me and my wife 
vomited a lot, so this is why I will not go and drink 
the medicine today although I have finished drinking 
the medication in the first round.” (Adult male).
Specific concerns regarding the mosquitocidal effect of 
ivermectin were also mentioned:
You gave someone medication to take and when 
mosquito bites you that mosquito dies, it will also 
kill flies and lice and bedbugs… Will that not affect 
the person who took that medicine? That is the rea-
son why some refuse.” (Alkalo).
However, though rarer, side effects were not always 
considered to be a negative consequence of the medica-
tion: some respondents described those symptoms as 
a clear sign that the medicine was having its intended 
effect.
Enabling factors for individual involvement in the MDA
The most significant enabling factors at all stages 
included: recognizing malaria as a health concern, believ-
ing the trial’s benefits, and attending the sensitization 
meetings.
Recognizing malaria as a health concern
Both the qualitative and quantitative data showed that 
although there is a general perception that malaria 
has substantially declined in the last few years (63% 
of respondents), it is still considered the most serious 
health concern in the intervention area as stated by IDI 
respondents. Despite being a medically pluralistic popu-
lation that uses Western biomedicine, herbalists and 
marabouts, respondents reported that going to health 
facilities is the preferred (87%) and most common option 
when they experience malaria symptoms for themselves 
(60%) or a child (44%) (Table 4).
Inhability to perform income-generating activities was 
cited as the most common non-health impact of malaria 
(78%), followed by missing household responsibilities 
(67%), and missing school (57%). However, the costs 
associated with malaria medication (45%), visiting the 
health facility (41%), and transport to the health facility 
(38%) were also named as important consequences of 
malaria (Table  4). Furthermore, the total self-reported 
costs of the last malaria-related visit to the health center 
(the accumulating costs of medication, fees, food, and 
transport) were significantly associated with increased 
adherence to the trial for each outcome variable: those 
who paid more were more likely to enrol, take the medi-
cation at least once, and have high adherence (Additional 
file 1: Table S1).
Local communities examined the costs associated with 
malaria not only as the result of the direct investment 
necessary to treat it, but also as the cost derived from 
having to go to the health facility during the busiest time 
of the year:
“When [field nurse] and team come here, I gather 
all my family and ask them to go and take the medi-
cine. I make sure all the children take the medicine 
for three times. I know I am comfortable when they 
are healthy. I will not be visiting the healthy facil-
ity always, I have been spending two, three hundred 
dalasi to buy medicine; therefore, when I am to stay 
healthy without paying a dalasi, do you think I will 
not take that seriously?” (Adult male).
“When the person develops any health problem is 
his own responsibility. From here to Basse the fare is 
seventy dalasi and whilst you are in Basse you can-
not stay all day without food; therefore, if you people 
come all the way from Basse and bring us medica-
tion here if we accept taking the medication is for 
our own good and whoever refuses to take the medi-
cation refuses at his own detriment.” (Adult male).
Perceived benefits of the trial
The most common perceived benefits of participating in 
the trial were “improved health” (70%) and preventing 
malaria (45%). Believing on the trial’s benefits was signifi-
cantly associated with higher levels of adherence in both 
bi- and multi-variate analysis (Additional file 1: Table S1). 
Though only a sparse number of respondents cited access 
to medical personnel or transportation as a benefit on 
their own, when prompted, 68% and 50%, respectively, 
said these factors were important trial’s benefits (Table 4).
“Our thoughts with MRC are that they are good and 
they have good medication, and if you are enrolled 
with the MRC, if you happen to get sick, they give 
you free transport from your home to the health 
facility. After treatment they send you home without 
paying anything and when they give you medication, 
you will not pay anything either.” (TBA female).
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Receiving the medication was explained along the same 
line of thought, not necessarily as an individual health 
protective measure, but as a benefit some members of the 
family should receive on behalf of the other:
“My elder brother is a motor cycle mechanic. He 
works the whole day and before he comes back is 
already late. My father is also a farmer who goes 
and chases animals at the farms from morning until 
evening to make sure that the farm is not invaded 
by animals, and the other two are women that are 
in the compound are all breastfeeding, so they can’t 
come. That is why for me as I have time I came to 
participate in the MDA.” (Adult female).
Attending community sensitization meetings
42% of surveyed women and 38% of surveyed men 
(41%, n = 349, of all those surveyed) reported that they 
attended the sensitization meetings in their villages 
(Table 5). Based upon the data from those surveyed, 52% 
of the attendants were 26–49  years of age. Only 3% of 
sensitization meeting attendees were girls aged 12–17, 
many of whom reported during interviews that they 
were too busy with household responsibilities during the 
meeting times. 
Although IDI respondents were not able to report 
many details about the information provided at the 
Table 4 Trial beliefs and malaria health‑seeking behaviors of 
survyed respondents
n = 864 n (%)
Believe malaria to be a problem
 Yes 220 (25)
 Yes, but less now than in past 544 (63)
 No 32 (4)
 Does not know 35 (4)
 No answer/missing 33 (4)
Non‑health impacts of malaria, prompted, could choose 
multiple (n = 561)
 Costs of health facility 229 (41)
 Costs of medicines 251 (45)
 Costs of transport 215 (38)
 Missed work 440 (78)
 Missed school 359 (57)
 Missed household responsibilities 374 (67)
 None 6 (1)
 Does not know 14 (3)
 Other 2 (0)
Benefits to trial, unprompted, could choose multiple
 None 58 (7)
 Access to study medicine 49 (6)
 Access to medical personnel 7 (1)
 Access to other medicines 4 (0)
 Improved health 609 (70)
 Access to transportation 1 (0)
 Material benefits 1 (0)
 Prevents malaria 389 (45)
 Does not know 61 (7)
 No answer 5 (1)
Benefit: access to medical personnel, prompted
 Yes 586 (68)
 No 122 (14)
 Does not know 81 (9)
 No answer/missing 75 (9)
Benefit: access to transportation, prompted
 Yes 431 (50)
 No 277 (32)
 Does not know 84 (10)
 No answer 72 (8)
Preferred treatment for malaria
 Nothing 7 (1)
 Treat at home 27 (3)
 Village health worker 7 (1)
 Health facility 748 (87)
 MRC 61 (7)
 Other 3 (0)
 Does not know 6 (1)
 No answer 5 (1)
Treatment sought for last malaria: self, could choose multiple
 Nothing 1 (0)
Table 4 (continued)
n = 864 n (%)
 Treat at home 23 (3)
 Go to VHW 23 (3)
 Go to health facility 518 (60)
 Go to traditional healer 3 (0)
 Go to MRC 26 (3)
 Other 4 (0)
 Does not know 7 (1)
 No answer 1 (0)
 Non‑applicable 281 (33)
Treatment sought for last malaria: child, could choose 
multiple
 Nothing 0 (0)
 Treat at home 10 (1)
 Go to VHW 8 (1)
 Go to health facility 383 (44)
 Go to traditional healer 1 (0)
 Go to MRC 12 (1)
 Other 6 (1)
 Does not know 1 (0)
 No answer 0 (0)
 Non‑applicable 188 (22)
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community sensitization meetings—and in some cases 
mentioned the meeting was held in a different language 
than the one spoken in the village—they were generally 
informed about the main focus (malaria) and activities 
(medicine distribution) of the trial, as well as the fact that 
they were not obliged to participate. IDI respondents also 
referred to the sensitization meetings as means to secure 
access to material benefits potentially available through 
their long-term collaboration with MRC:
“When studies like this are conducted in a village, 
try by all means to allow 3 or 4 people from your 
family to be part of the study (…) I said this because 
when there is future benefit for example this [other 
MRC trial in area], when your compound is not par-
ticipating in that project you don’t benefit from this 
project.” (Adult male).
Social influence
Social influence emerged as an essential factor in all 
phases of the trial—as both a barrier and facilitating fac-
tor. Respondents mentioned they waited to decide on 
whether or not to take the medication until after they 
saw the potential side effects it had on other people they 
know. Physical and social closeness within these villages 
facilitates this logic. Several respondents mentioned 
that when external visitors come to the village to intro-
duce a specific intervention, they prefer to postpone their 
decision to take part on it until the announced services 
are actually provided, and they can learn from other 
villagers’ experiences. In this particular case, commu-
nity members’ experiences with the first rounds of MDA 
influenced respondents’ decision-making processes sub-
sequent rounds:
“Early on we were scared to drink the medicine 
because some people were not talking good about 
the medicine (…) Some were saying that the medi-
cine is good, others were saying that if you drink the 
medicine it will make you vomit, dizzy, you can have 
diarrhea and weak body from it. This is what scared 
us in taking the medication at the initial stage (…) 
All this information comes out from our conversa-
tions because sometimes during our conversations 
you will meet with your good friends who will attest 
to you that this medication is very good, and it is 
very effective.” (Adult female).
Unanimously agreeing with a particular course of 
action was reported as a sign of cohesion at the village, 
compound, and household levels, in that order of author-
ity and decision-making power. It was believed that these 
authority figures should act as caretakers and enforce 
their decisions as a way to benefit the entire village.
“Well in this situation if the whole village decides on 
something, I can’t dispute it. I will just agree to the 
decision made by the village leaders, because wher-
ever the village stands that is where I will be.” (Adult 
male).
“When a whole village is doing something, and you 
are not doing the same, they consider you differently.” 
(Adult female).
IDI respondents often reported not having informa-
tion about those not taking the medication, or referred to 
decliners as isolated cases or negative examples of com-
munity members that could be internally addressed:
“Yes, a few numbers of them didn’t want to partici-
pate in the study. (…) But in general, all the com-
pounds are participating (…) the lost people whom 
you know that they are not educated, and they don’t 
listen to what the educated people are preaching to 
them, they are the people who spread bad rumours 
that MRC takes people’s blood (…) In any commu-









Needed permision to partici‑
pate
156 (60) 436 (82) 592 (75) < 0.0001
Spouse took medication 121 (41) 195 (35) 316 (37) 0.066
Compound head took medi‑
cation
158 (54) 334 (59) 492 (58) 0.11
Attended sensitization meet‑
ing
112 (38) 237 (42) 349 (41) 0.268
Table 6 Associations between social infleunce factors and outcome variables across genders. Odds ratio (95% confidence interval)
Bold values are statistically significant with a 95% confidence interval
Social influence Consent/enrollment Coverage Self reported: high adherence
Men Women Men Women Men Women
Needed permission to participate 0.8 (0.4–1.6) 4.4 (2.2–9.1) 1.3 (0.7–2.4) 3.7 (2.3–6.2) 1.5 (0.8–2.6) 2.12 (1.3–3.5)
Spouse took medication 3.5 (1.8–6.9) 2.6 (1.3–5.0) 2.5 (1.4–4.5) 1.5 (1.0–2.3) 2.6 (1.5–4.5) 2.3 (1.6–3.3)
Compound head took medication 1.1 (0.6–1.9) 2.0 (1.1–3.3) 1.9 (1.1–3.3) 1.5 (1.0–2.2) 1.1 (0.7–2.0) 1.2 (0.8–1.8)
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nity those kinds of people exist. Even in our village, 
there are a few of them here, but people will not lis-
ten to them because everyone knows what is good 
and bad, and in such a situation we know how to 
handle such people in our community.” (VDC Chair-
man).
Although following the decisions of the majority 
is a well-established social norm, our data also show 
instances of disagreement among heads of household and 
village leaders. In those cases, heads of household used 
their authority to prevent members of their families from 
taking part in the study:
“I went to [the coast]. When I came back, my elder 
daughter, I saw the card with her, she went and 
drink the medicine. I asked my daughter, ‘How you 
got this paper?’ and she said, ‘it was giving to me by 
MRC people.” I asked the mother, the mother said 
she was not aware. I was very angry that time, I took 
the card from my daughter and I keep it. I told the 
mother that ‘I think I told you that I do not have 
interested of this program, so why in the absence of 
me you sent my daughter to go and take the medi-
cine?’ So, I was angry.” (Adult male).
Having a spouse adhere to the trial was significantly 
associated with increased adherence for both men and 
women (Table 6). Women and minors, regardless of their 
age or marital status, were expected to consult with their 
husbands or caretakers (or their representatives in case of 
absence) about their potential adherence to the trial prior 
to providing informed consent. Women were signifi-
cantly more likely to require permission to enrol in the 
trial and needing permission was significantly associated 
with increased adherence (Tables 5, 6).
“I: As a woman, do you agree with reason given by 
your household head about not to participate in the 
trial?
R: I will discuss with my husband, try to convince 
him to participate because it is good. When I discuss 
with him, if he agrees, we will join, but if he did not 
agree then I will not join the trial.” (Adult female).
“When they came for enrolment in this compound 
my mother was not around—she went to Basse to 
sell. The field worker found me here and asked me 
to come and enrol. I told him that I can’t give you 
my consent in the absence of my mother, because I 
need to seek consent from her first. Then the field 
worker reacted and said to me ‘you are a grownup 
person you can decide for yourself.’ I was not happy 
about that reaction from the field worker and I still 
insisted that I can’t give consent without my mother 
(…) Your elder is just your elder, and you know eve-
ryone has a position in a family, and for her, she is 
my parent. And the rest of the children, I am also 
their elder. Anything I am supposed to do I need per-
mission from her. If she authorizes, I proceed with it; 
if she doesn’t give me permission, I stop it, so I can’t 
go beyond her decision.” (Adult female).
Respondents mentioned their capacity to influence 
their social environment by advising others about the 
benefits of working with MRC, which was seen as a form 
of protecting the interests of the village. Acknowledging 
that elders act as role models for the village, fieldwork-
ers strived to involve this sector of the population from 
early stages of the process by physically bringing them to 
their distribution point and having them motivate others 
to participate:
“Since the beginning of the MDA when the Alkalo 
and the village elders came, all the elders came as 
one group and the drugs were given to them (…) He 
was the first person who came (…) Because they see 
their elders taking it, why not them? I think this is 
the step they are following. Seeing their elders tak-
ing it, their grandfathers, fathers taking it in front of 
them, then they should be behind them.” (MRC Field 
Nurse).
The role of MRC
MRC’s long-standing presence in the study area also 
held considerable influence in trial decision-making and 
adherence. Respondents expressed high appreciation for 
receiving—what they consider—health care in their own 
village and mentioned MRC’s presence as an important 
facilitating factor to increased access to health-care in 
general. This appreciation was reported to be retributed 
with unconditional support and trust in MRC activities. 
In fact, those who were first told of the trial by an MRC 
employee were significantly more likely to take the study 
medicine at least once (Additional file 1: Table S1):
“For me and my family, I will never step back when it 
comes to MRC work.” (VDC Chairman).
“Yes, I always tell my people to go and take the medi-
cine, I tell them all the time, I always tell them that 
MRC does not give medicine that would make peo-
ple sick; they give medicine to improve our health.” 
(Adult male).
In some cases, community members assumed a more 
active role and became advocates for the organization:
“My concern regarding the study is that there are 
people who know why they are drinking this medi-
cation, but there are others whom you know they 
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are drinking this medication, but they don’t know 
why they are drinking this medication. They are just 
drinking it for the sake of drinking. So that being 
the case, I will take that responsibility before the 
second round. I will go and meet with these people 
within the compound and talk to them about why 
they are drinking this medication so that they will 
know. If not, in the second round when it is time for 
the MDA, they will start to take excuses by saying ‘I 
am going to the garden and other places.’ But if they 
are informed, the second round will be much better.” 
(Village mobilizer, male).
Negative past experiences, widely spread rumours 
regading MRC financially gaining from the sell of peo-
ple’s blood, and questions regarding research practices 
also acted as arguments to decline involvement with this 
particular initiative:
“We were looking at MRC. Like when you participate 
in an MRC study, they will come for you, but when 
they find a sick person in the compound, they will 
not attend to the patient, but they will be interested 
in taking the healthy person and leave the sick one at 
home, and that is where we think is faulty. Secondly, 
we were thinking like when they recruit children in 
their study, they will take them and bleed them, and 
you know? People who eat sorrel don’t have a lot of 
blood. This was the problem. We started discussing 
with them all that, but they just passed us and left. 
We didn’t, this was the issue.” (Adult male).
Discussion
MDA requires active individual and community involve-
ment to secure efficacy of treatment [6, 7]. This mixed-
methods study builds upon previous literature by 
showing that adherence to MDA is influenced by a 
multiplicity of individual, social, and implementation 
considerations constantly interacting and influencing 
decision-making at each and every stage of the MDA 
process. The results of this study show that rather than 
a linear trajectory, involvement is subjected to multi-
ple revaluations from enrolment and consent to medi-
cine intake and adherence to treatment [34, 35]. Issues 
of social influence, concerns regarding secondary effects 
of the medication, costs associated with malaria, and 
acceptability of the implementing organization, among 
other factors, differently affect decision-making pro-
cesses throughout the trial.
The role that family and community members play 
on decision making is well known within The Gambian 
context [8]. These results support the notion that peo-
ple’s level of involvement with and adherence to the trial 
is heavily influenced by the opinions, perceptions, and 
actions of their spouses, parents, compound heads, and 
community leaders. Respondents reported that unani-
mously supporting a particular course of action or deci-
sion made at the village level is a highly valued social 
norm; therefore, people are further influenced by social 
pressure to comply with what has been agreed upon by 
the community as a whole. Taking part in this particular 
intervention was described as an expression to support 
the communal decision of receiving the MRC and the 
trial medication—a decision that could render benefits 
not only for the individual, but also for the household, 
compound, and the entire village, both immediately and 
in the future [36].
However, this social influence is expressed differently 
between genders and across the different positions indi-
vidually held within the village and the household. For 
women in particular, social factors were highly influen-
tial. Women who required permission to take part in the 
trial, for example, were significantly more likely to enrol, 
take the medication at least once, and self-report high 
adherence than those who reported not needing permis-
sion. Later on, however, women that initially accepted 
to enrol and attempted medicine intake, reported hav-
ing stopped the medication due to a lack of privacy dur-
ing the process of the pregnancy tests as it might elicit 
rumours within the village. Social influence acts in this 
case as a facilitating factor for enrolment, but also as a 
deterrent for further adherence to treatment. Similarly, 
having a spouse take the medication was significantly 
associated with increased enrolment, coverage, and high 
adherence for both men and women. However, men 
were still less likely to report high adherence, support-
ing previous arguments about men’s hesitations regard-
ing MDA [37]. These findings highlight the importance 
of MDA community strategies that target gender-specific 
contextual factors to address the particular concerns and 
needs of the local population [6]. Beyond their direct 
impact on coverage and adherence, issues of privacy and 
autonomy should be analysed in their ethical dimension 
as predictors of inclusion among particularly vulner-
able populations, such as women of child-bearing age, in 
implementation research [37–39].
Similarly, attending the sensitization meeting was 
found to be associated with consenting to enrol in the 
trial, taking the medication the medications at least once, 
and adherence to treatment. Although this association 
may be linked to the importance of information provi-
sion on individual decision-making, this conclusion is 
overly simple. For example, 60% of respondents sampled 
did not attend sensitization meetings, but 84% consented 
to enrolment in the trial. Attending the sensitization 
meeting loses significance with enrolment and coverage 
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in the multi-variable analysis, demonstrating that other 
factors—such as perceived benefits—are concurrently 
involved in the decision-making process.
Previous studies have shown that the decision to take 
part in a trial in low-income settings often precedes 
information provision [40] and is made on the basis of 
non-health related arguments [41]. Expectations gener-
ated through the informal spread of information has been 
identified as particularly relevant, also in The Gambian 
context [8]. The political connotations of the sensitiza-
tion process from the respondents’ point of view exem-
plify these dynamics. In this study, community members 
reported to use sensitization meetings to make them-
selves and their families visible in the village and MRC-
supporting members, as this may render them eligible 
for any potential benefits. Additionally, by being present 
at the meetings, community members expressed their 
political power as part of an internal decision-making 
processes in the village and could demonstrate their posi-
tion as supporters of the community’s decision.
Local village dynamics should also be considered while 
explaining the behaviour of those who enrolled in the 
intervention but had no intention of taking the medica-
tion, as well as those who were willing to just partially 
adhere. This can be interpreted as a non-confrontational 
and contextually-appropriate resistance strategy that 
allows villagers to remain autonomous in their personal 
decision-making in the context of power imbalances exis-
ing among community members and sparked by MRC’s 
presence. MRC’s particular influence and importance 
within The Gambia has been extensively documented 
[41–43] and this study supports this: respondents at 
large expressed trust in the organization and the desire to 
accept what they had to offer, particularly as they viewed 
essential services like transportation and access to 
increased medical care as benefits of the trial. This close 
interplay between individual decision-making and larger 
social dynamics should be considered when explaining 
enrolment and consent that does not translate into actual 
medicine intake [35].
Concerns about the potential side effects of the medi-
cation were reported as one of the main reasons to reject 
or interrupt treatment at different stages of the MDA. 
Although the data do not support a direct association 
between symptoms reported by the study respond-
ents and the specific medications used in this MDA (all 
adverse events were reported regardless of their rela-
tion to the medication), it is important to point out that 
symptoms such as fever, headache, nausea, vomiting, 
dizziness, and itching have been previously reported for 
the medications used in this trial [15, 44]. Community 
concerns regarding safety of IVM’s mosquitocidal effect 
in humans should be seriously considered and adequately 
addressed in existing communication spaces with local 
communities, as they can overlap with those reported 
side effects and influence the uptake of and adherence to 
interventions.
Adding to the complexity of the decision-making pro-
cess, the data support that the direct and indirect costs 
associated with having malaria (particularly the cost of 
the last malaria-related visit to the health facility) are of 
importance throughout all phases of the trial [11]. This 
continues to hold true when all other factors, such as 
social influences and individual demographics are con-
sidered. The possibility of receiving preventative treat-
ment directly in their villages to avoid these expenses acts 
as an important justification to individually take part in 
the trial and motivate others, especially within the same 
family unit, to do the same.
There are important limitations in this study. At the 
moment of writing this manuscript, access to final fig-
ures of coverage and adherence for the general trial that 
could serve as reference to contrast the results has not 
been possible. Although this study only aimed to cap-
ture trends in coverage and adherence that could inform 
future MDA rounds, both coverage and adhrence data 
were below the ones originally targeted for this trial dur-
ing the first year of implementation. The data hereby pre-
sented, however, cannot be extrapolated to the general 
trial as this study could not include elegibility criteria in 
the calculations.
There were also methodological challenges to accu-
rately assess individual involvement in MDA. This study 
utilized two different approaches to assess the surveyed 
respondents’ consent and enrolment, coverage, and 
adherence: self-reported data and in-hand trial par-
ticipation cards. Both approaches showed important 
limitations. In the case of self-reporting, it was difficult 
to frame survey questions in such a way that accurately 
responded to specific medication intake during each 
administration, in each one of the days that it was pro-
vided, and during the three rounds of MDA.The fact that 
this MDA included two different medications—often not 
distinguished by respondents—in each administration 
further complicated matters. The question was finally 
posed as “How many times did you take the medica-
tion during the MDA?”; this question cannot assess the 
sequence of intake or allow for us to calculate per-round 
coverage, but reflects the recollection of single times in 
which it happened. Field workers were trained on how 
to deal with questions or confusion from respondents. 
For the latter approach, difficulties derived from the pos-
session of participation cards by village members. Many 
respondents reported that their cards were either lost or 
collected by MRC personnel after the trial. In addition, 
there were discrepancies between some respondents 
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having self-reported not taking the medicine but having 
clinical cards with recorded doses. Although only minor 
differences emerged from the data collected through 
these different approaches, these discrepancies highlight 
the need to improve the data collection methods of trials 
and their concurrent studies to accurately measure pro-
gress towards elimination [21].
Of note, the word ‘participant’ was purposely avoided 
in this manuscript. The rationale for this decision is two-
fold: first, there is a need to avoid any confusion between 
individuals involved in this sub-study (respondents) and 
individuals involved the trial in general; second, and 
more important, this study made evident that local popu-
lations have a broader understanding of what participat-
ing in a trial of this nature means. It can include activities 
such as being in touch with clinical teams to replicate 
information at the village level or cleaning and organ-
izing the space where the medicine administration will 
take place. Since assessing participation in its political 
and social dimensions is beyond the scope of this paper, 
the decision was made to avoid the term and to report on 
this subject in upcoming manuscripts.
Conclusion
Factors discussed in the previous sections demonstrate 
the complexity of interactions influencing adherence 
to multidose MDA regimens. From consent to medi-
cine intake, local residents constantly revaluated their 
involvement with the trial based on multiple indi-
vidual and social factors, including potential or actual 
side effects of the medication, the timing of the MDA 
in regard to economic demands, previous information 
regarding the intervention, as well as perceptions and 
experiences of other family members and community 
members in relation to the medication and its provid-
ers. In the same vein that authors have proposed to 
reimagine malaria treatment, diagnostics, and surveil-
lance during this elimination era [45, 46], this study 
demonstrates the need to invest resources to improve 
critical indicators and more accurately report adher-
ence to emerging elimination tools. In the case of MDA, 
it is essential that more complex ideas about individual 
and community involvement are incorporated in the 
understanding of the internal heterogeneity that could 
significantly limit the effectiveness of the intervention.
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